Physician profile
Jonathan D Bell
NPI 1437147873
$3,968.20
in general payments reported to CMS, 2019-2025
26 companies · $595 in 2025
The $595 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $477 · 2021: $676 · 2022: $705 · 2023: $706 · 2024: $414 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,518.01 | 2019-2025 | Linzess, Creon, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $436.69 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $403.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $382.34 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $273.73 | 2019-2024 | Epclusa |
| Braintree Laboratories, INC. | $198.25 | 2019-2023 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $130.22 | 2019-2023 | Rebyota |
| Novo Nordisk INC | $107.91 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $68.07 | 2020 | |
| Pfizer INC. | $55.78 | 2024 | |
| Concordia Pharmaceuticals INC. | $46.60 | 2019 | |
| Corcept Therapeutics | $38.00 | 2024 | Korlym |
| Merck Sharp & Dohme LLC | $37.58 | 2022-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Alexion Pharmaceuticals, INC. | $33.98 | 2024-2025 | Strensiq |
| Qol Medical, LLC | $27.73 | 2024 | Sucraid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.46 | 2024 | Farxiga |
| Allergan, INC. | $22.12 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.07 | 2023 | Jardiance |
| Ardelyx, INC. | $21.19 | 2023 | Ibsrela |
| Medtronic, INC. | $19.74 | 2023 | Interstim |
| Celgene Corporation | $19.70 | 2024 | Zeposia |
| Lilly USA, LLC | $17.90 | 2024 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $16.62 | 2025 | |
| Echosens North America, INC. | $15.37 | 2019 | |
| Janssen Biotech, INC. | $14.04 | 2025 | Tremfya |
| Xeris Pharmaceuticals, INC. | $13.73 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.